Sumgen Biotech's Novel ADC Candidate SG2918 For Injection Has Commenced Firs-In-Human Study
Hangzhou, China - December 27, 2023 - Hangzhou Sumgen Biotech Co., Ltd (hereinafter referred to as "Sumgen Biotech") is delighted to announce the successful administration of the first dose of our proprietary ADC candidate, SG2918 for injection. This marks another key milestone in the clinical study of SG2918 injection, following the successful kick-off meeting on November 28th. This clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of SG2918 for injection in patients with advanced malignant solid tumors. The study was led by Professor Zhengbo Song, principal investigator from Zhejiang Cancer Hospital.